Post-hoc analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET) (73) and Randomized Evaluation of Long-Term Anticoagulant Therapy with Dabigatran etexilate (RE-LY) (96) trials suggest that DOACs have a more beneficial effect on renal function decline than warfarin, which has been confirmed in multiple observational studies (76, 94, 95, 97–99). Here, F10 is linked to atrial fibrillation.